J., S. B., F., M. A., C.A., R. S., E., G. C., C., H. M., E.M., C. G., . . . M., M. (2022). Safety and efficacy of ribociclib plus letrozole in patients with HR+, HER2– advanced breast cancer: Results from the Spanish sub-population of the phase 3b CompLEEment-1 trial.
Citação norma ChicagoJ., Salvador Bofill, et al. Safety and Efficacy of Ribociclib Plus Letrozole in Patients With HR+, HER2– Advanced Breast Cancer: Results From the Spanish Sub-population of the Phase 3b CompLEEment-1 Trial. 2022.
Citação norma MLAJ., Salvador Bofill, et al. Safety and Efficacy of Ribociclib Plus Letrozole in Patients With HR+, HER2– Advanced Breast Cancer: Results From the Spanish Sub-population of the Phase 3b CompLEEment-1 Trial. 2022.
Nota: a formatação da citação pode não corresponder 100% ao definido pela respectiva norma.